Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A treatment paradigm also applicable to patients in Southeast Asia

Cancer Treatment Reviews

Volumn 35, Issue 4, 2009, Pages 345-353

  Lu, Heming ^a   Peng, Luxing ^a   Yuan, Xianbin ^a   Hao, Yanrong ^a   Lu, Zhiping ^a   Chen, Jiaxin ^a   Cheng, Jinjian ^a   Deng, Shan ^a   Gu, Junzhao ^a   Pang, Qiang ^a   Qin, Jian ^a  

^a PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

Author keywords

Concurrent chemoradiotherapy; Image guided radiotherapy; Immunotherapy; Intensity modulated radiotherapy; Locally advanced disease; Nasopharyngeal carcinoma; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CANCER VACCINE; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DENDRITIC CELL VACCINE; DOCETAXEL; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYUREA; LMP 2 PEPTIDE; OXALIPLATIN; PACLITAXEL; PEPTIDE VACCINE; SORAFENIB; TAXANE DERIVATIVE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; BRACHYTHERAPY; BRAIN NECROSIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMPUTER ASSISTED RADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CRANIAL NERVE PARALYSIS; CYTOTOXIC T LYMPHOCYTE; DERMATITIS; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; ENDOCRINE DISEASE; EPSTEIN BARR VIRUS; GAMMA KNIFE RADIOSURGERY; HEARING LOSS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PROGNOSIS; RADIATION DOSE; RADIATION INJURY; RECURRENT CANCER; REVIEW; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIA, SOUTHEASTERN; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67349111339     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.01.002     Document Type: Review

References (89)

1. Marks J.E., Philips J.L., and Menck H.R. The national cancer data base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 83 (1998) 582-588
2. Jiong L., Berrino F., and Coebergh J.W.W. Variation in survival for adults with nasopharyngeal cancer in Europe, 1978-1989. Eur J Cancer 34 (1998) 2162-2166
3. Hsu M.M., and Tu S.M. Nasopharyngeal carcinoma in Taiwan: clinical manifestations and results of therapy. Cancer 52 (1983) 362-368
4. Lee A.W.M., Poon Y.F., Foo W., et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 23 (1992) 261-270
5. Lu H., and Yao M. The current status of intensity-modulated radiation therapy in the treatment of nasopharyngeal carcinoma. Cancer Treat Rev 34 (2008) 27-36
6. Chen W.Z., Zhou D.L., and Luo K.S. Long-term observation after radiotherapy for nasopharyngeal carcinoma (NPC). Int J Radiat Oncol Biol Phys 16 (1989) 311-314
7. Qin D., H Y., Yan J., et al. Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation. Cancer 61 (1988) 1117-1124
8. Sanguineti G., Geara F.B., Garden A.S., et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys 37 (1997) 985-996
9. Ngan R.K., Yiu H.H., Lau W.H., et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Am Oncol 13 (2002) 1252-1258
10. Taamma A., Fandi A., Azli N., et al. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer 86 (1999) 1101-1108
11. Siu L.L., Czaykowski P.M., and Tannock I.F. Phase I/II study of the CAPBLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. J Clin Oncol 16 (1998) 2514-2521
12. Fnadi A., Altun M., Azli N., Armand J.P., and Cvitovic E. Nasopharyngeal cancer, epidemiology, staging and treatment. Semin Oncol 21 (1994) 382-397
13. Al-Sarraf M., LeBlanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup 0099. J Clin Oncol 16 (1998) 1310-1317
14. Al-Sarraf M., LeBlanc M., Giri P.G., et al. Superiority of 5-year survival with chemoradiotherapy vs. radiotherapy in patients with locally advanced nasopharyngeal cancer. Intergroup 0099 phase III study: final report [abstract]. Proc Am Soc Clin Oncol 20 (2001) 227a
15. Altun M., Fandi A., Dupuis O., Cvitkovic E., Krajina Z., and Eschwege F. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 32 (1995) 859-877
16. Lee A.W., Foo W., Mang O., et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): an encouraging reduction in both incidence and mortality. Int J Cancer 103 (2003) 680-685
17. Chan A.T., Teo P.M., and Johnson P.J. Nasopharyngeal carcinoma. Ann Oncol 13 (2002) 1007-1015
18. Tan E.H., Chua E.T., Wee J., et al. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in Asian patients with nasopharyngeal carcinoma: toxicities and preliminary results. Int J Radiat Oncol Biol Phys 45 (1999) 597-601
19. Chan A.T.C., Teo P.M.L., and Johnson P.J. Controversies in the management of locaregionally advanced nasopharyngeal carcinoma. Curr Opin Oncol 10 (1998) 219-225
20. Chan A.T., Teo P.M., Leung T.W., et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 33 (1995) 569-577
21. Al-Sarraf M., and McLaughlin P. Nasopharynx carcinoma: choice of treatment. Int J Radiat Oncol Biol Phys 33 (1995) 761-763
22. Cheng S.H., Liu T.W., Jian J.J., et al. Concomitant chemotherapy and radiotherapy for locally advanced nasopharyngeal carcinoma. Cancer J Sci Am 3 (1997) 100-106
23. Cheng S.K., Jian J.J., Tsai S.Y., et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 48 (2000) 1323-1330
24. Lin J.C., Chen K.Y., Jan J.S., and Hsu C.Y. Partially hyperfractionated accelerated radiotherapy and concurrent chemotherapy for advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 36 (1996) 1127-1136
25. Lin J.C., Jan J.S., and Hsu C.Y. Pilot study of concurrent chemotherapy and radiotherapy for stage IV nasopharyngeal cancer. Am J Clin Oncol 20 (1997) 6-10
26. Lin J.C., Jan J.S., Hsu C.Y., Liang W.M., Jiang R.S., and Wang W.Y. Phase III study of concurrent chemotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21 (2003) 631-637
27. Wee J., Tan E.H., Tai B.C., et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23 (2005) 6730-6738
28. Wee J., Tan E.H., Tai B.C., et al. Final report of SQNP01-a phase III randomized trial comparing RT with chmoRT for locally advanced nasopharyngeal cancer [abstract]. Int J Radiat Oncol Biol Phys 66 (2006) S16
29. Chan A.T., Teo P.M., Ngan R.K., et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20 (2002) 2038-2044
30. Chan A.T., Leung S.F., Ngan R.K., et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97 (2005) 536-539
31. Lee A.W., Lau W.H., Tung S.T., et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23 (2005) 6966-6975
32. Gearaa F.B., Sanguineti G., Tucker S.L., et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiother Oncol 43 (1997) 53-61
33. Yi J.L., Gao L., Huang X.D., et al. Nasopharyngeal carcinoma treated by radical radiotherapy alone; ten-year experience of a single institution. Int J Radiat Oncol Biol Phys 65 (2006) 161-168
34. Chen Y., Liu M.Z., Liang S.B., et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. Int J Radiat Oncol Biol Phys 71 (2008) 1356-1364
35. Zhang L., Zhao C., Peng P.J., et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 23 (2005) 8461-8468
36. Huncharek M., and Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1528 patients from six randomized trials. Am J Clin Oncol 25 (2002) 219-223
37. Levine P.H., Connelly R.R., and Easton J.M. Demographic patterns for nasopharyngeal carcinoma in the United Stated. Int J Cancer 26 (1980) 741-748
38. Burt R.D., Vaughan T.L., and Mcknight B. Descriptive epidemiology and survival analysis of nasopharyngeal carcinoma in the United States. Int J Cancer 52 (1992) 549-556
39. Reddy S.P., Rasian W.F., Gooneratne S., Kathuria S., and Marks J.E. Prognostic significance of keratinizing in nasopharyngeal carcinoma. Am J Otolaryngol 16 (2005) 103-108
40. Thephamongkhol K., Browman G., Wang R., et al. Chemoradiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: a meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases [abstract 5522]. Proc Am Soc Clin Oncol 23 (2004) 491
41. Baujat B., Audry H., Bourhis J., et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64 (2006) 47-56
42. Zhang L., Zhao C., Ghimire B.R., et al. The role of concurrent chemoradiation in the treatment of locally advanced nasopharyngeal carcinoma among endemic area: a meta-analysis of the phase III randomized trials [abstract]. Proc Am Soc Clin Oncol 26 (2008) 6032
43. Kam M.K., Chau R.M., Suen J., Choi P.H., and Teo P.M. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of does escalation. Int. J Radiat Oncol Biol Phys 56 (2003) 145-157
44. Xia P., Fu K.K., Wong G.W., Akazawa C., and Verhey L.J. Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 48 (2000) 329-337
45. Cheng J.C., Chao K.S., and Low D. Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int J Cancer 96 (2001) 126-131
46. Hunt M.A., Zelefsky M.J., Wolden S., et al. Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys 49 (2001) 623-632
47. Kristensen C.A., Kjaer-Kristoffersen F., Sapru W., Berthelsen A.K., Loft A., and Specht L. Nasopharyngeal carcinoma. Treatment planning with IMRT and 3D conformal radiotherapy. Acto Oncol 46 (2007) 214-220
48. Lee S.W., Back G.M., Yi B.Y., et al. Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 65 (2006) 152-160
49. Wolden S.L., Chen W.C., Pfister D.G., Kraus D.H., Berry S.L., and Zelefsky M.J. Intensity-modulated radiation therapy (IMRT) for nasopharyngeal cancer: update of the memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 64 (2006) 57-62
50. Sultanem K., Shu H., Xia P., et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 48 (2000) 711-722
51. Wang J, Bai S, Chen N, et al. Preliminary study on the clinical feasibility and effect of online cone beam computer tomography-guided intensity-modulated radiotherapy for nasopharyngeal cancer. Radiother Oncol in press. doi: 10.1016/j.radonc.2008.08.017.
52. Yeo W., Leung T.W., Chan A.T., et al. A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer 34 (1998) 2027-2031
53. Tan E.H., Khoo K.S., Wee J., et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 10 (1999) 235-237
54. Airoldi M., Pedani F., Marchionatti S., et al. Carboplatin plus toxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma. Tumori 88 (2002) 273-276
55. Wong A.S., Soo R.A., Lu J.J., et al. Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma. Ann Oncol 17 (2006) 1152-1157
56. Fu K.K., and Phillips T.L. Biologic rationale of combined radiotherapy and chemotherapy. Hematol Oncol Clin North Am 5 (1991) 737-751
57. Moos P., and Fitzpatrick F. Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits. Cell Growth Diff 9 (1998) 687-697
58. Mason K.A., Kishi K., Hunter N., et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 5 (1999) 4191-4199
59. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol in press. doi: 10.1200/JCO.2008.18.1545.
60. Peters G.J., Bergman A.M., Ruiz van Haperen V.M., Veerman G., Kuiper C.M., and Braakhuis B.J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 Suppl (1995) S72-S79
61. Foo K.F., Tan E.H., Leong S.S., et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 13 (2002) 150-156
62. Ma B.B., Tannock I.F., Pond G.R., Edmonds M.R., and Siu L.L. Chemotherapy with gemcitabine-containing regimens for locally advanced recurrent or metastatic nasopharyngeal carcinoma. Cancer 95 (2002) 2516-2523
63. Ngan R.K., Yiu H.H., Lau W.H., et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol 13 (2002) 1252-1258
64. Ciuleanu E., Irimie A., Ciuleanu T.E., Popita V., Todor N., and Ghilezan N. Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study. J Buon 13 (2008) 37-42
65. Chua D., Wei W.I., Sham J.S., and Au G.K. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. Jpn J Clin Oncol 38 (2008) 244-249
66. Li Y.H., Wang F.H., Jiang W.Q., et al. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol 62 (2008) 539-544
67. Thompson M.P., and Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 10 (2004) 803-821
68. Lin J.C., Wang W.Y., Chen K.Y., et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. New Engl J Med 350 (2004) 2461-2470
69. Lee S.P., Chan A.T., Cheung S.T., et al. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL response in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol 165 (2000) 573-582
70. Whatney B.M., Chan A.T., Rickinson A.B., Lee S.P., Lin C.K., and Johnson P.J. Frequency of Eptein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients. J Med Virol 67 (2002) 359-363
71. Straathof K.C., Bollard C.M., Popat U., et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105 (2005) 1898-1904
72. Chua D., Huang J., Zheng B., et al. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer 94 (2001) 73-80
73. Comoli P., Pedrazzoli P., Maccario R., et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epsten-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23 (2005) 8942-8949
74. Lin C.L., Lo W.F., Lee T.H., et al. Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 62 (2002) 6952-6958
75. Fujii M., Yamashita T., Ishiguro R., Tashiro M., and Kameyama K. Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx 29 (2002) 175-181
76. Sheen T.S., Huang Y.T., Chang Y.L., et al. Epstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma. Jpn J Cancer Res 90 (1999) 1285-1292
77. Chua D., Nicholls J., Sham J., and Au G. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 11-22
78. Rocha-Lima C.M., Soares H.P., Raez L.E., and Singal R. EGFR targeting of solid tumors. Cancer Control 14 (2007) 295-304
79. Chan A.T., Hsu M.M., Goh B.C., et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 23 (2005) 3568-3576
80. Chua D.T., Sham J.S., and Au G.K. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 39 (2003) 361-366
81. Bonner J.A., Harari P.M., Giralt J., et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab [Abstract 5507]. Proc Am Soc Clin Oncol 23 (2004) 489
82. Ma B., Hui E.P., King A., et al. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer Chemother Pharmacol 62 (2008) 59-64
83. Chua D.T., Wei W.I., Wong M.P., Sham J.S., Nicholls J., and Au G.K. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck 30 (2008) 863-867
84. Semenza G.L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Ann Rev Cell Dev Biol 15 (1999) 551-578
85. Harris A. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2 (2002) 38-47
86. Xueguan L., Xiaoshen W., Yongsheng Z., Chaosu H., Chunying S., and Yan F. Hypoxia inducible factor-1α and vascular endothelial growth factor expression are associated with a poor prognosis in patients with nasopharyngeal carcinoma receiving radiotherapy with carbogen and nicotinamide. Clin Oncol 20 (2008) 606-612
87. Hui E.P., Chan A.T., Pezzella F., et al. Coexpression of hypoxia inducible factor 1α and 2α, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8 (2002) 2595-2604
88. Ngan R.K., Lau W.H., Yip T.T., et al. Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy. Ann NY Acad Sci 945 (2001) 73-79
89. Yip K.W., Mocanu J.D., Au P.Y., et al. Combination Bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 11 (2005) 8131-8144